We see how essential personalized medicine is in your approach. The development of this medicine is the very foundation of the National PreciDIAB Center. Can you tell us about the PreciDIAB clinical study project in preparation within the IPL?
The Institut Pasteur de Lille is a founding member of the Center National PreciDIAB. The PreciDIAB – Institut Pasteur de Lille study is an important part of the PreciDIAB project. Our study first aims to identify the risk factors for entering type 2 diabetes and accelerated aging in people in precarious situations. We know that they are more exposed to this risk but we do not really know the weight of the risk factors, the role of insecurity, the interactions between all the factors, the mechanisms involved.
This is a major public health issue given the explosion of diabetes worldwide, and the deterioration of socio-economic conditions in many populations, including in France, and particularly in the North. We will therefore analyze the lifestyle (nutrition, sedentary lifestyle, sleep, stress, etc.), living conditions, psychological dimensions but also of course a whole series of biological markers, including the most modern (telomere length), the most sharp (metabolome and other omics), the microbiota, genetics… in more than 2,500 subjects.
The second part of the study will be an intervention study by acting on the levers highlighted during the cross-sectional study, the aim being to reduce the risk of diabetes and accelerated aging, but also to see what “works”. »(And if it works!).